Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
The use of surrogate end points as a basis for conclusions about therapy and drugs for cardiovascular disease is both praised and criticized as it has resulted in both successes and failures. Surrogate end points can lead to much faster approval of drugs, but the consequences of relying on such data...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 1999-08, Vol.282 (8), p.790-795 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 795 |
|---|---|
| container_issue | 8 |
| container_start_page | 790 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 282 |
| creator | Temple, Robert |
| description | The use of surrogate end points as a basis for conclusions about therapy and drugs for cardiovascular disease is both praised and criticized as it has resulted in both successes and failures. Surrogate end points can lead to much faster approval of drugs, but the consequences of relying on such data must be carefully weighed. |
| doi_str_mv | 10.1001/jama.282.8.790 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69987197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>191287</ama_id><sourcerecordid>44183649</sourcerecordid><originalsourceid>FETCH-LOGICAL-a326t-c2f82abd4b46201284d7a526168d3c091e8795b129db35438fe8e2a069e1d2b83</originalsourceid><addsrcrecordid>eNpdkM1Lw0AQxRdRbK1eBS-yePCWuB_JfpwktFaFigf1HDbZaUlNmrqbFfzvXWlFcC4DMz8e7z2EzilJKSH0Zm06kzLFUpVKTQ7QmOZcJTzX6hCNCdEqkZnKRujE-zWJQ7k8RiNKMsEl1WM0Lxzgl-BcvzID4Cfj3sF5XFj4CD-HoceF9-A9nhpnm_7T-Dq0xuFZ48F4wDMXVv72FB0tTevhbL8n6G1-9zp9SBbP94_TYpEYzsSQ1GypmKlsVmWCEcpUZqXJmaBCWV4TTUFJnVeUaVvxPONqCQqYIUIDtaxSfIKud7pb138E8EPZNb6GtjUb6IMvhdYq5pIRvPoHrvvgNtFbySjlWkjBInS5h0LVgS23rumM-yp_64nAxQ6ILf99dTQu-TciY212</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211396762</pqid></control><display><type>article</type><title>Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Temple, Robert</creator><creatorcontrib>Temple, Robert</creatorcontrib><description>The use of surrogate end points as a basis for conclusions about therapy and drugs for cardiovascular disease is both praised and criticized as it has resulted in both successes and failures. Surrogate end points can lead to much faster approval of drugs, but the consequences of relying on such data must be carefully weighed.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.282.8.790</identifier><identifier>PMID: 10463719</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Biomarkers ; Cardiovascular Agents - therapeutic use ; Cardiovascular disease ; Cardiovascular Diseases - prevention & control ; Clinical trials ; Clinical Trials as Topic ; Drug Approval ; Drug Evaluation ; FDA approval ; Humans ; Medical research ; Pharmaceuticals ; Risk ; Treatment Outcome ; United States ; United States Food and Drug Administration</subject><ispartof>JAMA : the journal of the American Medical Association, 1999-08, Vol.282 (8), p.790-795</ispartof><rights>Copyright American Medical Association Aug 25, 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a326t-c2f82abd4b46201284d7a526168d3c091e8795b129db35438fe8e2a069e1d2b83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.282.8.790$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.282.8.790$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3338,27922,27923,76259,76262</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10463719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Temple, Robert</creatorcontrib><title>Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>The use of surrogate end points as a basis for conclusions about therapy and drugs for cardiovascular disease is both praised and criticized as it has resulted in both successes and failures. Surrogate end points can lead to much faster approval of drugs, but the consequences of relying on such data must be carefully weighed.</description><subject>Biomarkers</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Drug Approval</subject><subject>Drug Evaluation</subject><subject>FDA approval</subject><subject>Humans</subject><subject>Medical research</subject><subject>Pharmaceuticals</subject><subject>Risk</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkM1Lw0AQxRdRbK1eBS-yePCWuB_JfpwktFaFigf1HDbZaUlNmrqbFfzvXWlFcC4DMz8e7z2EzilJKSH0Zm06kzLFUpVKTQ7QmOZcJTzX6hCNCdEqkZnKRujE-zWJQ7k8RiNKMsEl1WM0Lxzgl-BcvzID4Cfj3sF5XFj4CD-HoceF9-A9nhpnm_7T-Dq0xuFZ48F4wDMXVv72FB0tTevhbL8n6G1-9zp9SBbP94_TYpEYzsSQ1GypmKlsVmWCEcpUZqXJmaBCWV4TTUFJnVeUaVvxPONqCQqYIUIDtaxSfIKud7pb138E8EPZNb6GtjUb6IMvhdYq5pIRvPoHrvvgNtFbySjlWkjBInS5h0LVgS23rumM-yp_64nAxQ6ILf99dTQu-TciY212</recordid><startdate>19990825</startdate><enddate>19990825</enddate><creator>Temple, Robert</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>19990825</creationdate><title>Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?</title><author>Temple, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a326t-c2f82abd4b46201284d7a526168d3c091e8795b129db35438fe8e2a069e1d2b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Biomarkers</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Drug Approval</topic><topic>Drug Evaluation</topic><topic>FDA approval</topic><topic>Humans</topic><topic>Medical research</topic><topic>Pharmaceuticals</topic><topic>Risk</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Temple, Robert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Temple, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>1999-08-25</date><risdate>1999</risdate><volume>282</volume><issue>8</issue><spage>790</spage><epage>795</epage><pages>790-795</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>The use of surrogate end points as a basis for conclusions about therapy and drugs for cardiovascular disease is both praised and criticized as it has resulted in both successes and failures. Surrogate end points can lead to much faster approval of drugs, but the consequences of relying on such data must be carefully weighed.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>10463719</pmid><doi>10.1001/jama.282.8.790</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 1999-08, Vol.282 (8), p.790-795 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69987197 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Biomarkers Cardiovascular Agents - therapeutic use Cardiovascular disease Cardiovascular Diseases - prevention & control Clinical trials Clinical Trials as Topic Drug Approval Drug Evaluation FDA approval Humans Medical research Pharmaceuticals Risk Treatment Outcome United States United States Food and Drug Administration |
| title | Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T00%3A30%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20Surrogate%20Markers%20Adequate%20to%20Assess%20Cardiovascular%20Disease%20Drugs?&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Temple,%20Robert&rft.date=1999-08-25&rft.volume=282&rft.issue=8&rft.spage=790&rft.epage=795&rft.pages=790-795&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.282.8.790&rft_dat=%3Cproquest_pubme%3E44183649%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211396762&rft_id=info:pmid/10463719&rft_ama_id=191287&rfr_iscdi=true |